Posted by Michael Wonder on 07 Mar 2025
Amivantamab in combination with pemetrexed disodium heptahydrate and carboplatin for the treatment of patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer
6 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of amivantamab with pemetrexed disodium heptahydrate and carboplatin in the NHS in England.
Amivantamab, when used in combination with pemetrexed disodium heptahydrate and carboplatin, is not recommended for the first-line treatment of adults with advanced, activating EGFR exon 20 insertion mutation positive non-small-cell lung cancer.
